245 / 278
CONSOLIDATED FINANCIAL REPORT | EXPLANATORY NOTES
245
23. OTHER EXPENSES
These are detailed as follows:
The Group incurred Euro 73 million in research and development costs in 2015 (Euro 71 million in 2014).
24. SHARE OF NET PROFIT/(LOSS) OF EQUITY-ACCOUNTED COMPANIES
This is detailed as follows:
Further information can be found in Note 3. Equity-accounted investments.